disulfiram and vorinostat
disulfiram has been researched along with vorinostat in 8 studies
Research
Studies (8)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 7 (87.50) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
Authors
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Liu, H; Ramakrishnan, R; Rice, AP | 1 |
Bullen, CK; Durand, CM; Laird, GM; Siliciano, JD; Siliciano, RF | 1 |
Cheng, WJ; Churchill, MJ; Ellett, AM; Gorry, PR; Gray, LR; Jacobson, JC; Lewin, SR; Lu, HK; Moso, MA; On, H; Papaioannou, C; Purcell, DF; Raison, JA; Roberts, E; Wesselingh, SL | 1 |
Bartek, J; Bartkova, J; Bouchal, J; Cwiertka, K; Gachechiladze, M; Gursky, J; Hodny, Z; Korinkova, G; Kurfurstova, D; Majera, D; Mistrik, M; Simkova, D; Skrott, Z; Steigerova, J | 1 |
Blennow, K; Bumpus, N; Burger, D; Chang, J; Dantanarayana, A; Evans, VA; Fisher, K; Gisslen, M; Hagenauer, M; Heck, CJS; Howell, BJ; Lau, JSY; Lee, S; Lewin, SR; McMahon, JH; Palmer, S; Rasmussen, TA; Solomon, A; Symons, J; Tennakoon, S; Wu, G; Zerbato, JM; Zetterberg, HH; Zuck, P | 1 |
Reviews
1 review(s) available for disulfiram and vorinostat
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Other Studies
7 other study(ies) available for disulfiram and vorinostat
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Short communication: SAHA (vorinostat) induces CDK9 Thr-186 (T-loop) phosphorylation in resting CD4+ T cells: implications for reactivation of latent HIV.
Topics: Acetaldehyde Dehydrogenase Inhibitors; CD4-Positive T-Lymphocytes; Cell Line; Cyclin T; Cyclin-Dependent Kinase 9; Disulfiram; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Humans; Hydroxamic Acids; Jurkat Cells; Phosphorylation; Positive Transcriptional Elongation Factor B; Virus Activation; Virus Latency; Vorinostat | 2015 |
New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.
Topics: Anti-HIV Agents; Azepines; Bryostatins; CD4-Positive T-Lymphocytes; Cell Cycle Proteins; Depsipeptides; Disulfiram; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Humans; Hydroxamic Acids; Indoles; Ionomycin; Lymphocyte Activation; Nuclear Proteins; Panobinostat; Tetradecanoylphorbol Acetate; Transcription Factors; Triazoles; Virus Latency; Vorinostat | 2014 |
Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells.
Topics: Acetamides; Astrocytes; Azepines; Cell Line; Cell Survival; Depsipeptides; Disulfiram; Fetus; Histone Deacetylase Inhibitors; HIV-1; Humans; Hydroxamic Acids; Indoles; Macrophages; Neurons; Panobinostat; Piperazines; Primary Cell Culture; Transcription, Genetic; Triazoles; Virus Activation; Virus Latency; Virus Replication; Vorinostat | 2016 |
Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram.
Topics: Cell Line, Tumor; Disulfiram; DNA Repair; Gene Expression Regulation, Neoplastic; Humans; Male; Molecular Targeted Therapy; PC-3 Cells; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; PTEN Phosphohydrolase; Radiation Tolerance; Recombinational DNA Repair; Stress, Physiological; Tumor Suppressor Protein p53; Vorinostat | 2019 |
Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal.
Topics: Disulfiram; Drug Therapy, Combination; HIV Infections; Humans; Virus Latency; Vorinostat | 2022 |